| NCT06679881 | Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE | RECRUITING | PHASE3 | 2025-02-01 | 2028-12 | 2028-12 |
| NCT06669754 | Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE | RECRUITING | PHASE3 | 2024-12-01 | 2026-08 | 2026-08 |
| NCT06343779 | Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema | RECRUITING | PHASE3 | 2024-02-26 | 2026-03 | 2026-03 |
| NCT05396105 | Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema | ENROLLING_BY_INVITATION | PHASE2, PHASE3 | 2022-12-28 | 2027-06 | 2027-06 |
| NCT05047185 | Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II | COMPLETED | PHASE2 | 2022-04-19 | 2025-06-30 | 2025-06-30 |
| NCT04618211 | Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema | COMPLETED | PHASE2 | 2021-02-03 | 2023-03-01 | 2022-09-23 |